文献速递乳腺癌

整合列线图预测乳腺肿瘤HER2表达:临床、超声与光声成像方法

Integrated nomogram to predict HER2 expression in breast tumor: Clinical, Ultrasound, and Photoacoustic imaging approaches.
PubMed 文献 · Eur J Cancer · 2024-08-03

研究纳入301例乳腺肿瘤,按7:3分为训练集与验证集,构建仅临床因素(ModA)、临床加超声因素(ModB)、临床加超声及光声成像衍生氧饱和度(ModC)三个模型预测HER2表达。ModA的AUC为0.756(95%CI 0.69-0.82),ModB增至0.866(95%CI 0.82-0.91),ModC最高为0.877(95%CI 0.83-0.92),提示整合临床、超声与光声成像数据可提高预测HER2表达的准确性。

要点

  • 共纳入301例乳腺肿瘤,按HER2阳性(3+或2+伴基因扩增)与HER2阴性分组,按7:3分为训练集与验证集。
  • ModA(仅临床因素)AUC为0.756(95%CI 0.69-0.82),ModB(临床加超声)AUC为0.866(95%CI 0.82-0.91)。
  • ModC(临床、超声及光声成像衍生氧饱和度)AUC最高为0.877(95%CI 0.83-0.92)。

核心结论

  • 研究结果提示,整合临床、超声与光声成像数据可显著提高预测HER2表达的准确性。
  • 对于个体化乳腺癌治疗,该整合模型可提供全面且可重复的决策支持工具。

研究设计与样本

  • 研究纳入301例乳腺肿瘤,按HER2阳性(3+或2+伴基因扩增)与HER2阴性(低于3+且2+不伴基因扩增)分组。
  • 样本按7:3比例分为训练集与验证集。
  • 采用t检验、卡方检验和秩和检验进行统计分析,并通过单因素和多因素logistic回归识别预测因素。
  • 构建三个模型:ModA(仅临床因素)、ModB(临床加超声因素)、ModC(临床、超声及光声成像衍生氧饱和度SO2)。

主要发现

  • ModA的AUC为0.756(95%CI 0.69-0.82)。
  • ModB的AUC增至0.866(95%CI 0.82-0.91)。
  • ModC表现最佳,AUC为0.877(95%CI 0.83-0.92)。
  • 上述结果提示,整合临床、超声与光声成像数据的综合模型(ModC)在预测HER2表达方面表现最佳。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HER2 is a key biomarker for breast cancer treatment and prognosis. Traditional assessment methods like immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are effective but costly and time-consuming. Our model incorporates these methods alongside photoacoustic imaging to enhance diagnostic accuracy and provide more comprehensive clinical insights. MATERIALS AND METHODS: A total of 301 breast tumors were included in this study, divided into HER2-positive (3+ or 2+ with gene amplification) and HER2-negative (below 3+ and 2+ without gene amplification) groups. Samples were split into training and validation sets in a 7:3 ratio. Statistical analyses involved t-tests, chi-square tests, and rank-sum tests. Predictive factors were identified using univariate and multivariate logistic regression, leading to the creation of three models: ModA (clinical factors only), ModB (clinical plus ultrasound factors), and ModC (clinical, ultrasound, and photoacoustic imaging-derived oxygen saturation (SO2)). RESULTS: The area under the curve (AUC) for ModA was 0.756 (95 % CI: 0.69-0.82), ModB increased to 0.866 (95 % CI: 0.82-0.91), and ModC showed the highest performance with an AUC of 0.877 (95 % CI: 0.83-0.92). These results indicate that the comprehensive model combining clinical, ultrasound, and photoacoustic imaging data (ModC) performed best in predicting HER2 expression. CONCLUSION: The findings suggest that integrating clinical, ultrasound, and photoacoustic imaging data significantly enhances the accuracy of predicting HER2 expression. For personalised breast cancer treatment, the integrated model could provide a comprehensive and reproducible decision support tool.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Chen J, Yin Y, Li G, et al. Integrated nomogram to predict HER2 expression in breast tumor: Clinical, Ultrasound, and Photoacoustic imaging approaches. Eur J Cancer. 2024. PMID: 39111206. doi:10.1016/j.ejca.2024.114259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。